
Seawolf Therapeutics, a biotechnology startup based in San Diego, has raised $100 million in funding to develop new treatments using its proprietary DNA delivery technology.
The company announced its emergence from stealth along with the funding, which includes seed and Series A financing. Versant Ventures led the seed round and also participated in the Series A round alongside MPM BioImpact and Novartis Venture Fund.
Other investors include Eli Lilly and Company, CRISPR Therapeutics, Sixty Degree Capital, Alexandria Venture Investments, and Pathway to Cures, the philanthropic venture arm of the National Bleeding Disorders Foundation.
Seawolf will use the new funding to advance its TRIDENT™ DNA delivery platform which is designed to help deliver DNA into cells and support longer-lasting production of therapeutic proteins.
“Seawolf is charting a new course in patient care through LNP-based DNA medicines,” said Elizabeth Alcamo, Ph.D., president and CEO. “With a strong syndicate of investors and our collaboration with Sanofi, we are well-positioned to execute on our next stage of growth, which will include advancing our lead program for metabolic diseases and collaborating with Sanofi in its mission to develop therapies for patient unmet needs.”
Unlike some existing RNA-based treatments that provide short-term results, Seawolf’s technology aims to deliver DNA-based treatments that can produce therapeutic proteins for longer periods. The platform also allows repeated dosing, giving doctors the potential to adjust or supplement treatment over time.
“Nucleic acid-based therapies have advanced dramatically over the past decade,” said Tom Woiwode, Ph.D., managing director at Versant and chair of Seawolf’s board. “The Seawolf team is now delivering on the promise of using DNA to drive robust and long-term expression of therapeutic proteins directly from the patient’s own cells. I look forward to seeing this groundbreaking technology transform treatment options for patients.”
The company said its TRIDENT technology has shown positive early results in preclinical studies involving primates and mice. These studies covered potential applications in metabolic and rare diseases.
Alongside the funding announcement, Seawolf revealed a research collaboration and exclusive licensing agreement with Sanofi. The partnership will focus on developing treatments for bleeding disorders and other undisclosed medical conditions.
Under the agreement, Seawolf could receive up to $1.2 billion in research, development and commercial milestone payments, along with additional royalties on product sales.
Seawolf Therapeutics aims to use its DNA delivery platform across several medical fields including genetic disease treatment and the development of therapies that produce therapeutic proteins inside the body.
The company is backed by leading biotechnology investors including Versant Ventures, MPM BioImpact, and Novartis Venture Fund.